CN114601760A - Oral composition - Google Patents
Oral composition Download PDFInfo
- Publication number
- CN114601760A CN114601760A CN202110917912.5A CN202110917912A CN114601760A CN 114601760 A CN114601760 A CN 114601760A CN 202110917912 A CN202110917912 A CN 202110917912A CN 114601760 A CN114601760 A CN 114601760A
- Authority
- CN
- China
- Prior art keywords
- oral
- composition
- present
- garcinia cambogia
- extract
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- ZMJBYMUCKBYSCP-UHFFFAOYSA-N Hydroxycitric acid Chemical compound OC(=O)C(O)C(O)(C(O)=O)CC(O)=O ZMJBYMUCKBYSCP-UHFFFAOYSA-N 0.000 claims abstract description 55
- AIXAANGOTKPUOY-UHFFFAOYSA-N carbachol Chemical compound [Cl-].C[N+](C)(C)CCOC(N)=O AIXAANGOTKPUOY-UHFFFAOYSA-N 0.000 claims abstract description 41
- 229960004484 carbachol Drugs 0.000 claims abstract description 41
- 208000025157 Oral disease Diseases 0.000 claims abstract description 39
- 208000030194 mouth disease Diseases 0.000 claims abstract description 39
- 239000004480 active ingredient Substances 0.000 claims abstract description 30
- 239000000284 extract Substances 0.000 claims abstract description 28
- 241000593508 Garcinia Species 0.000 claims abstract description 27
- 235000000885 Garcinia xanthochymus Nutrition 0.000 claims abstract description 27
- 150000003839 salts Chemical class 0.000 claims abstract description 22
- 230000002265 prevention Effects 0.000 claims abstract description 18
- 230000004224 protection Effects 0.000 claims abstract description 18
- 238000011282 treatment Methods 0.000 claims abstract description 16
- 230000006872 improvement Effects 0.000 claims abstract description 14
- XSXCZNVKFKNLPR-SDQBBNPISA-N carbazochrome Chemical compound NC(=O)N/N=C/1C(=O)C=C2N(C)CC(O)C2=C\1 XSXCZNVKFKNLPR-SDQBBNPISA-N 0.000 claims abstract description 6
- 229960002631 carbazochrome Drugs 0.000 claims abstract description 6
- 239000008194 pharmaceutical composition Substances 0.000 claims description 28
- 208000007565 gingivitis Diseases 0.000 claims description 21
- 208000003265 stomatitis Diseases 0.000 claims description 18
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 17
- 206010006326 Breath odour Diseases 0.000 claims description 16
- 239000004615 ingredient Substances 0.000 claims description 16
- 201000001245 periodontitis Diseases 0.000 claims description 16
- 208000032139 Halitosis Diseases 0.000 claims description 15
- 201000010099 disease Diseases 0.000 claims description 14
- 208000002925 dental caries Diseases 0.000 claims description 12
- 201000011486 lichen planus Diseases 0.000 claims description 11
- 208000028169 periodontal disease Diseases 0.000 claims description 11
- 206010007134 Candida infections Diseases 0.000 claims description 9
- 208000007027 Oral Candidiasis Diseases 0.000 claims description 9
- 241000287411 Turdidae Species 0.000 claims description 9
- 201000003984 candidiasis Diseases 0.000 claims description 9
- 230000002757 inflammatory effect Effects 0.000 claims description 9
- 201000004328 Pulpitis Diseases 0.000 claims description 8
- 206010037464 Pulpitis dental Diseases 0.000 claims description 8
- 208000025865 Ulcer Diseases 0.000 claims description 8
- 231100000397 ulcer Toxicity 0.000 claims description 7
- 230000003902 lesion Effects 0.000 claims description 6
- 230000000694 effects Effects 0.000 abstract description 33
- 235000013305 food Nutrition 0.000 abstract description 27
- 230000003449 preventive effect Effects 0.000 abstract description 2
- 230000001225 therapeutic effect Effects 0.000 abstract description 2
- 210000000515 tooth Anatomy 0.000 description 47
- 206010061218 Inflammation Diseases 0.000 description 26
- 230000004054 inflammatory process Effects 0.000 description 26
- 210000000214 mouth Anatomy 0.000 description 21
- 208000024891 symptom Diseases 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 17
- 239000000606 toothpaste Substances 0.000 description 17
- 208000002193 Pain Diseases 0.000 description 16
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 15
- 210000001519 tissue Anatomy 0.000 description 15
- 229940034610 toothpaste Drugs 0.000 description 14
- 239000000796 flavoring agent Substances 0.000 description 12
- 235000003599 food sweetener Nutrition 0.000 description 11
- 239000000546 pharmaceutical excipient Substances 0.000 description 11
- 238000002360 preparation method Methods 0.000 description 11
- 239000003765 sweetening agent Substances 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 11
- 208000032843 Hemorrhage Diseases 0.000 description 10
- 235000013361 beverage Nutrition 0.000 description 10
- 239000003085 diluting agent Substances 0.000 description 10
- 230000002401 inhibitory effect Effects 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- 230000000740 bleeding effect Effects 0.000 description 9
- 238000000605 extraction Methods 0.000 description 9
- 235000019634 flavors Nutrition 0.000 description 9
- 239000007788 liquid Substances 0.000 description 9
- -1 oral cleansers Substances 0.000 description 9
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 8
- 239000000243 solution Substances 0.000 description 8
- 230000033228 biological regulation Effects 0.000 description 7
- 239000003814 drug Substances 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000000638 stimulation Effects 0.000 description 7
- 108010000684 Matrix Metalloproteinases Proteins 0.000 description 6
- 102000002274 Matrix Metalloproteinases Human genes 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 239000011230 binding agent Substances 0.000 description 6
- 239000002552 dosage form Substances 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 235000013376 functional food Nutrition 0.000 description 6
- 239000003755 preservative agent Substances 0.000 description 6
- 210000005239 tubule Anatomy 0.000 description 6
- 108090000695 Cytokines Proteins 0.000 description 5
- 102000004127 Cytokines Human genes 0.000 description 5
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 5
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 5
- 239000003086 colorant Substances 0.000 description 5
- 210000002200 mouth mucosa Anatomy 0.000 description 5
- 230000003239 periodontal effect Effects 0.000 description 5
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 4
- 208000006595 Necrotizing Ulcerative Gingivitis Diseases 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 229910000019 calcium carbonate Inorganic materials 0.000 description 4
- 239000006071 cream Substances 0.000 description 4
- 229960005150 glycerol Drugs 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000008101 lactose Substances 0.000 description 4
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 4
- 239000002674 ointment Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 230000004044 response Effects 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 241000894006 Bacteria Species 0.000 description 3
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 241000222122 Candida albicans Species 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- 241000196324 Embryophyta Species 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 208000034619 Gingival inflammation Diseases 0.000 description 3
- 101001013150 Homo sapiens Interstitial collagenase Proteins 0.000 description 3
- 208000035154 Hyperesthesia Diseases 0.000 description 3
- 206010020751 Hypersensitivity Diseases 0.000 description 3
- 102000000380 Matrix Metalloproteinase 1 Human genes 0.000 description 3
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 3
- 208000008312 Tooth Loss Diseases 0.000 description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 3
- 235000010443 alginic acid Nutrition 0.000 description 3
- 229920000615 alginic acid Polymers 0.000 description 3
- 208000002399 aphthous stomatitis Diseases 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 210000000988 bone and bone Anatomy 0.000 description 3
- 230000001680 brushing effect Effects 0.000 description 3
- 239000001768 carboxy methyl cellulose Substances 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 3
- 230000006378 damage Effects 0.000 description 3
- 238000000354 decomposition reaction Methods 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 235000020510 functional beverage Nutrition 0.000 description 3
- 210000004195 gingiva Anatomy 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000003906 humectant Substances 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002324 mouth wash Substances 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 239000000419 plant extract Substances 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 3
- 229940079776 sodium cocoyl isethionate Drugs 0.000 description 3
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 239000000080 wetting agent Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 206010067510 Contact stomatitis Diseases 0.000 description 2
- 206010016654 Fibrosis Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 101000990915 Homo sapiens Stromelysin-1 Proteins 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 108090001005 Interleukin-6 Proteins 0.000 description 2
- 206010028034 Mouth ulceration Diseases 0.000 description 2
- 206010055670 Necrotising ulcerative gingivostomatitis Diseases 0.000 description 2
- 208000007117 Oral Ulcer Diseases 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- 102100030416 Stromelysin-1 Human genes 0.000 description 2
- 238000000692 Student's t-test Methods 0.000 description 2
- 229920001615 Tragacanth Polymers 0.000 description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 208000026935 allergic disease Diseases 0.000 description 2
- 239000000305 astragalus gummifer gum Substances 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000006399 behavior Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 208000034158 bleeding Diseases 0.000 description 2
- 210000004204 blood vessel Anatomy 0.000 description 2
- 239000004067 bulking agent Substances 0.000 description 2
- 235000010216 calcium carbonate Nutrition 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- OSGAYBCDTDRGGQ-UHFFFAOYSA-L calcium sulfate Chemical compound [Ca+2].[O-]S([O-])(=O)=O OSGAYBCDTDRGGQ-UHFFFAOYSA-L 0.000 description 2
- 229940095731 candida albicans Drugs 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 235000014633 carbohydrates Nutrition 0.000 description 2
- 235000014171 carbonated beverage Nutrition 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000006037 cell lysis Effects 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- QMVPMAAFGQKVCJ-UHFFFAOYSA-N citronellol Chemical compound OCCC(C)CCC=C(C)C QMVPMAAFGQKVCJ-UHFFFAOYSA-N 0.000 description 2
- 239000000084 colloidal system Substances 0.000 description 2
- 230000007123 defense Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 210000003298 dental enamel Anatomy 0.000 description 2
- 210000003074 dental pulp Anatomy 0.000 description 2
- 210000004268 dentin Anatomy 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 239000003792 electrolyte Substances 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 239000003623 enhancer Substances 0.000 description 2
- RRAFCDWBNXTKKO-UHFFFAOYSA-N eugenol Chemical compound COC1=CC(CC=C)=CC=C1O RRAFCDWBNXTKKO-UHFFFAOYSA-N 0.000 description 2
- 239000000835 fiber Substances 0.000 description 2
- 230000004761 fibrosis Effects 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 238000005187 foaming Methods 0.000 description 2
- 235000013373 food additive Nutrition 0.000 description 2
- 239000002778 food additive Substances 0.000 description 2
- 229940029982 garlic powder Drugs 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 208000024693 gingival disease Diseases 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000028709 inflammatory response Effects 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- CDOSHBSSFJOMGT-UHFFFAOYSA-N linalool Chemical compound CC(C)=CCCC(C)(O)C=C CDOSHBSSFJOMGT-UHFFFAOYSA-N 0.000 description 2
- 229940057995 liquid paraffin Drugs 0.000 description 2
- 210000002540 macrophage Anatomy 0.000 description 2
- 235000019359 magnesium stearate Nutrition 0.000 description 2
- 239000000463 material Substances 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 229940051866 mouthwash Drugs 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 239000013588 oral product Substances 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 210000002741 palatine tonsil Anatomy 0.000 description 2
- 239000006072 paste Substances 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 230000033764 rhythmic process Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 229960002920 sorbitol Drugs 0.000 description 2
- 235000013599 spices Nutrition 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 229960004793 sucrose Drugs 0.000 description 2
- BDHFUVZGWQCTTF-UHFFFAOYSA-M sulfonate Chemical compound [O-]S(=O)=O BDHFUVZGWQCTTF-UHFFFAOYSA-M 0.000 description 2
- 150000003464 sulfur compounds Chemical class 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- MGSRCZKZVOBKFT-UHFFFAOYSA-N thymol Chemical compound CC(C)C1=CC=C(C)C=C1O MGSRCZKZVOBKFT-UHFFFAOYSA-N 0.000 description 2
- RUVINXPYWBROJD-ONEGZZNKSA-N trans-anethole Chemical compound COC1=CC=C(\C=C\C)C=C1 RUVINXPYWBROJD-ONEGZZNKSA-N 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 201000008587 ulcerative stomatitis Diseases 0.000 description 2
- 210000002396 uvula Anatomy 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 238000003809 water extraction Methods 0.000 description 2
- 235000010447 xylitol Nutrition 0.000 description 2
- 239000000811 xylitol Substances 0.000 description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 2
- 229960002675 xylitol Drugs 0.000 description 2
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 1
- FTLYMKDSHNWQKD-UHFFFAOYSA-N (2,4,5-trichlorophenyl)boronic acid Chemical compound OB(O)C1=CC(Cl)=C(Cl)C=C1Cl FTLYMKDSHNWQKD-UHFFFAOYSA-N 0.000 description 1
- 239000001490 (3R)-3,7-dimethylocta-1,6-dien-3-ol Substances 0.000 description 1
- KRLBLPBPZSSIGH-CSKARUKUSA-N (6e)-3,7-dimethylnona-1,6-dien-3-ol Chemical compound CC\C(C)=C\CCC(C)(O)C=C KRLBLPBPZSSIGH-CSKARUKUSA-N 0.000 description 1
- QMVPMAAFGQKVCJ-SNVBAGLBSA-N (R)-(+)-citronellol Natural products OCC[C@H](C)CCC=C(C)C QMVPMAAFGQKVCJ-SNVBAGLBSA-N 0.000 description 1
- CDOSHBSSFJOMGT-JTQLQIEISA-N (R)-linalool Natural products CC(C)=CCC[C@@](C)(O)C=C CDOSHBSSFJOMGT-JTQLQIEISA-N 0.000 description 1
- WUOACPNHFRMFPN-SECBINFHSA-N (S)-(-)-alpha-terpineol Chemical compound CC1=CC[C@@H](C(C)(C)O)CC1 WUOACPNHFRMFPN-SECBINFHSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- FSKNXCHJIFBRBT-UHFFFAOYSA-N 2-[2-[2-(dodecylamino)ethylamino]ethylamino]acetic acid Chemical compound CCCCCCCCCCCCNCCNCCNCC(O)=O FSKNXCHJIFBRBT-UHFFFAOYSA-N 0.000 description 1
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- 206010065687 Bone loss Diseases 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- NPBVQXIMTZKSBA-UHFFFAOYSA-N Chavibetol Natural products COC1=CC=C(CC=C)C=C1O NPBVQXIMTZKSBA-UHFFFAOYSA-N 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 241000546193 Clusiaceae Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- UDIPTWFVPPPURJ-UHFFFAOYSA-M Cyclamate Chemical compound [Na+].[O-]S(=O)(=O)NC1CCCCC1 UDIPTWFVPPPURJ-UHFFFAOYSA-M 0.000 description 1
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 1
- 208000002064 Dental Plaque Diseases 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 1
- 238000002965 ELISA Methods 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- 239000005770 Eugenol Substances 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 208000005232 Glossitis Diseases 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 206010061598 Immunodeficiency Diseases 0.000 description 1
- 208000029462 Immunodeficiency disease Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- 241000219171 Malpighiales Species 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000006679 Mentha X verticillata Nutrition 0.000 description 1
- 235000002899 Mentha suaveolens Nutrition 0.000 description 1
- 235000001636 Mentha x rotundifolia Nutrition 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010028116 Mucosal inflammation Diseases 0.000 description 1
- 201000010927 Mucositis Diseases 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 241000282376 Panthera tigris Species 0.000 description 1
- 239000004721 Polyphenylene oxide Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 206010037075 Protozoal infections Diseases 0.000 description 1
- UVMRYBDEERADNV-UHFFFAOYSA-N Pseudoeugenol Natural products COC1=CC(C(C)=C)=CC=C1O UVMRYBDEERADNV-UHFFFAOYSA-N 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 239000012980 RPMI-1640 medium Substances 0.000 description 1
- UEDUENGHJMELGK-HYDKPPNVSA-N Stevioside Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O UEDUENGHJMELGK-HYDKPPNVSA-N 0.000 description 1
- 206010042129 Stomatitis and ulceration Diseases 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 239000005844 Thymol Substances 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- YKTSYUJCYHOUJP-UHFFFAOYSA-N [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] Chemical compound [O--].[Al+3].[Al+3].[O-][Si]([O-])([O-])[O-] YKTSYUJCYHOUJP-UHFFFAOYSA-N 0.000 description 1
- 238000005299 abrasion Methods 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000007815 allergy Effects 0.000 description 1
- OVKDFILSBMEKLT-UHFFFAOYSA-N alpha-Terpineol Natural products CC(=C)C1(O)CCC(C)=CC1 OVKDFILSBMEKLT-UHFFFAOYSA-N 0.000 description 1
- 229940088601 alpha-terpineol Drugs 0.000 description 1
- WNROFYMDJYEPJX-UHFFFAOYSA-K aluminium hydroxide Chemical compound [OH-].[OH-].[OH-].[Al+3] WNROFYMDJYEPJX-UHFFFAOYSA-K 0.000 description 1
- 229940011037 anethole Drugs 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 230000002744 anti-aggregatory effect Effects 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 230000005784 autoimmunity Effects 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- JGQFVRIQXUFPAH-UHFFFAOYSA-N beta-citronellol Natural products OCCC(C)CCCC(C)=C JGQFVRIQXUFPAH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 229960003563 calcium carbonate Drugs 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- JUNWLZAGQLJVLR-UHFFFAOYSA-J calcium diphosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O JUNWLZAGQLJVLR-UHFFFAOYSA-J 0.000 description 1
- FUFJGUQYACFECW-UHFFFAOYSA-L calcium hydrogenphosphate Chemical compound [Ca+2].OP([O-])([O-])=O FUFJGUQYACFECW-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 229940043256 calcium pyrophosphate Drugs 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 208000020670 canker sore Diseases 0.000 description 1
- 235000010418 carrageenan Nutrition 0.000 description 1
- 239000000679 carrageenan Substances 0.000 description 1
- 229920001525 carrageenan Polymers 0.000 description 1
- 229940113118 carrageenan Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 239000010630 cinnamon oil Substances 0.000 description 1
- 235000000484 citronellol Nutrition 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 210000004513 dentition Anatomy 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000019821 dicalcium diphosphate Nutrition 0.000 description 1
- 235000019700 dicalcium phosphate Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960002986 dinoprostone Drugs 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 229940044165 dodicin Drugs 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 238000012407 engineering method Methods 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 229960002217 eugenol Drugs 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000029142 excretion Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000004088 foaming agent Substances 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 210000001983 hard palate Anatomy 0.000 description 1
- 210000003128 head Anatomy 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 1
- 230000009610 hypersensitivity Effects 0.000 description 1
- 238000007654 immersion Methods 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000007813 immunodeficiency Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004968 inflammatory condition Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 229940094522 laponite Drugs 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 229930007744 linalool Natural products 0.000 description 1
- 229940040145 liniment Drugs 0.000 description 1
- 239000000865 liniment Substances 0.000 description 1
- XCOBTUNSZUJCDH-UHFFFAOYSA-B lithium magnesium sodium silicate Chemical compound [Li+].[Li+].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[OH-].[Na+].[Na+].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].[Mg+2].O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3.O1[Si](O2)([O-])O[Si]3([O-])O[Si]1([O-])O[Si]2([O-])O3 XCOBTUNSZUJCDH-UHFFFAOYSA-B 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 238000002803 maceration Methods 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 229910000400 magnesium phosphate tribasic Inorganic materials 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000001683 mentha spicata herb oil Substances 0.000 description 1
- 229940041616 menthol Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 230000017074 necrotic cell death Effects 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 206010030983 oral lichen planus Diseases 0.000 description 1
- 229940023486 oral product Drugs 0.000 description 1
- 239000000668 oral spray Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 210000003254 palate Anatomy 0.000 description 1
- RUVINXPYWBROJD-UHFFFAOYSA-N para-methoxyphenyl Natural products COC1=CC=C(C=CC)C=C1 RUVINXPYWBROJD-UHFFFAOYSA-N 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 210000002379 periodontal ligament Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 239000011505 plaster Substances 0.000 description 1
- 229920003229 poly(methyl methacrylate) Polymers 0.000 description 1
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 description 1
- 239000004584 polyacrylic acid Substances 0.000 description 1
- 229920000570 polyether Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 229920001451 polypropylene glycol Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 238000010791 quenching Methods 0.000 description 1
- 230000000171 quenching effect Effects 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000003753 real-time PCR Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 239000010668 rosemary oil Substances 0.000 description 1
- 229940058206 rosemary oil Drugs 0.000 description 1
- 229940085605 saccharin sodium Drugs 0.000 description 1
- 239000010670 sage oil Substances 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-M salicylate Chemical compound OC1=CC=CC=C1C([O-])=O YGSDEFSMJLZEOE-UHFFFAOYSA-M 0.000 description 1
- 229960001860 salicylate Drugs 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 229960001462 sodium cyclamate Drugs 0.000 description 1
- AQMNWCRSESPIJM-UHFFFAOYSA-M sodium metaphosphate Chemical compound [Na+].[O-]P(=O)=O AQMNWCRSESPIJM-UHFFFAOYSA-M 0.000 description 1
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 description 1
- 210000001584 soft palate Anatomy 0.000 description 1
- 235000019721 spearmint oil Nutrition 0.000 description 1
- 238000005507 spraying Methods 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 229940013618 stevioside Drugs 0.000 description 1
- OHHNJQXIOPOJSC-UHFFFAOYSA-N stevioside Natural products CC1(CCCC2(C)C3(C)CCC4(CC3(CCC12C)CC4=C)OC5OC(CO)C(O)C(O)C5OC6OC(CO)C(O)C(O)C6O)C(=O)OC7OC(CO)C(O)C(O)C7O OHHNJQXIOPOJSC-UHFFFAOYSA-N 0.000 description 1
- 235000019202 steviosides Nutrition 0.000 description 1
- 125000000185 sucrose group Chemical group 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000012209 synthetic fiber Substances 0.000 description 1
- 229920002994 synthetic fiber Polymers 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 210000004876 tela submucosa Anatomy 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 229960000790 thymol Drugs 0.000 description 1
- 230000036346 tooth eruption Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 239000003860 topical agent Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000002137 ultrasound extraction Methods 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 239000004034 viscosity adjusting agent Substances 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 230000004580 weight loss Effects 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/38—Clusiaceae, Hypericaceae or Guttiferae (Hypericum or Mangosteen family), e.g. common St. Johnswort
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9783—Angiosperms [Magnoliophyta]
- A61K8/9789—Magnoliopsida [dicotyledons]
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
- A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
- A61K8/492—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid having condensed rings, e.g. indol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q11/00—Preparations for care of the teeth, of the oral cavity or of dentures; Dentifrices, e.g. toothpastes; Mouth rinses
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/40—Chemical, physico-chemical or functional or structural properties of particular ingredients
- A61K2800/59—Mixtures
- A61K2800/592—Mixtures of compounds complementing their respective functions
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Botany (AREA)
- Microbiology (AREA)
- Biotechnology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Birds (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oral & Maxillofacial Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Alternative & Traditional Medicine (AREA)
- Medical Informatics (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
Abstract
The present invention relates to an oral composition. The present invention relates to a composition for the prevention, improvement or treatment of gum protection or oral diseases, comprising a combination of Garcinia Cambogia (Garcinia Cambogia) extract, more preferably Garcinia Cambogia extract and carbachol (Carbazochrome) or a pharmaceutically acceptable salt thereof as active ingredients, and more particularly, to a composition having a preventive, improving or therapeutic effect on sensitive teeth. The composition of the present invention has little side effect, is safe to the human body and has excellent effects, and can be used as an oral hygiene composition, a pharmaceutical external composition or a food composition.
Description
Technical Field
The present invention relates to an oral composition for managing the oral cavity, and to a composition which has little side effect, is safe to the human body, and has an excellent effect on the protection of gums or the prevention, improvement, or treatment of oral diseases.
Background
It is well known that oral diseases are major factors inducing various clinical symptoms such as pain, chewing dysfunction, destruction of periodontal tissues, halitosis and sensitive teeth and causing tooth loss, and it is true that the causative factors of oral diseases are further increasing due to changes in dietary life.
On the other hand, the symptom of teeth called sensitive teeth or tooth hyperesthesia refers to a symptom that teeth are sore when eating sour fruit or drinking cold water, etc., and occurs when enamel and cementum are destroyed due to improper tooth brushing or gums are atrophic due to gum disease, and dentinal tubules protected by gums are exposed. In order to improve such sensitive tooth symptoms, toothpastes for preventing sensitive teeth have been developed, and treatments for filling exposed dentinal tubules with resin or the like have been carried out in dentistry. However, in the case of the conventional sensitive teeth exclusive use toothpaste using the sealing effect of dentinal tubules, fine powder containing an active ingredient is used to seal the dentinal tubules, but such powder generally has a problem that it is rapidly diluted during tooth brushing and most of it is washed away during rinsing with water, so that the tubules cannot be sealed and exposed again.
Recently, although attempts have been made to develop oral products using plant extracts, there still remain problems in that the effects thereof are insignificant.
Therefore, there is a need to develop an oral product that does not have the above-mentioned problems and is safe while having remarkably excellent efficacy on oral health using natural materials of plant origin (e.g., plant extracts).
Disclosure of Invention
Problems to be solved
The present invention provides a novel active ingredient safe to the human body and useful for oral health, i.e., a useful use of such an active ingredient, and aims to provide an oral composition comprising the above-mentioned active ingredient excellent in efficacy as an active ingredient.
In addition, the present invention aims to provide an oral hygiene composition, a pharmaceutical composition, a Quasi-drug (Quasi-drug) composition or a food composition using such a composition.
Means for solving the problems
In order to solve the above problems, the present invention provides an oral composition comprising an extract of Garcinia cambogia (Garcinia cambogia) which is a natural material source as an active ingredient. Further, the present invention provides an oral composition comprising (a) an extract of Garcinia cambogia and (b) Carbazochrome (Carbazochrome) or a pharmaceutically acceptable salt thereof as active ingredients.
More specifically, the present invention provides a use of a combination of Garcinia cambogia (Garcinia cambogia) extract, more preferably (a) Garcinia cambogia extract and (b) carbachol (Carbazochrome) or a pharmaceutically acceptable salt thereof, for protecting gums or preventing, ameliorating or treating oral diseases.
The present inventors have conducted studies for developing an oral composition which is harmless to the human body and shows effects of protecting gums or treating, preventing, improving and the like various oral diseases. As a result, it was confirmed that a composition containing a garcinia cambogia extract can have an excellent antibacterial effect, particularly an excellent effect of preventing, ameliorating or treating sensitive tooth symptoms, and the present invention was completed. Further, it was confirmed that a composition comprising both an extract of Garcinia cambogia and carbachol can have remarkably excellent effects due to the synergistic enhancement of the effects of gum protection or prevention, improvement and treatment of various oral diseases, and thus the present invention was completed.
The term "Garcinia Cambogia (Garcinia Cambogia)" as used in the present specification is a plant belonging to the Garcinia family (Clusiaceae) of the Tiger order (Malpighiales) that inhabits India and Indonesia and the like. At present, it is known as a diet supplement or the like because of its influence on weight loss.
In the present invention, the above garcinia cambogia extract can be extracted from various organs (e.g., leaves, roots, stems, branches, fruits, pericarps, seeds, etc.) of garcinia cambogia.
The term "extract" as used herein refers to an extract liquid itself such as an extract liquid obtained by extraction treatment of Garcinia cambogia, a diluted or concentrated solution of the above-mentioned extract liquid, a dried product obtained by drying the above-mentioned extract liquid, a roughly purified or purified product of the above-mentioned extract liquid, or a mixture thereof, and an extract of any formulation which can be formed from the extract liquid.
In one aspect of the present invention, the kind of the extraction solvent used for extracting the above garcinia cambogia is not particularly limited, and any solvent known in the art may be used. Non-limiting examples of the above extraction solvent may include any one or more solvents selected from the group consisting of water, distilled water, lower alcohols of C1 to C4, acetone, ether, benzene, chloroform, ethyl acetate, dichloromethane, n-hexane, hydrochloric acid, acetic acid, formic acid, diethyl ether, cyclohexane, dipropylene glycol, hexylene glycol, and 1, 3-butylene glycol, and the like.
Preferably, in another aspect of the present invention, the above garcinia cambogia extract is extracted with distilled water, a lower alcohol of C1 to C4, or a mixed solvent thereof.
In the present invention, the extraction method of extracting the above-described garcinia cambogia extract is not particularly limited, and may be extracted according to a method generally used in the art. The above extraction method may be hot water extraction, immersion extraction, reflux cooling extraction or ultrasonic extraction, and these may be performed alone or in combination of two or more methods. Preferably, the extraction may be by hot water extraction or maceration extraction methods.
In one aspect of the present invention, the content of the extract of Garcinia cambogia fruit is 0.0001 to 30 wt% of the total weight of the composition, preferably 0.001 to 20 wt% of the total weight of the composition.
In one aspect of the present invention, the carbachol (Carbazochrome) or a pharmaceutically acceptable salt thereof may be, for example, carbachol sulfonate, carbachol sodium sulfonate, carbachol salicylate, carbachol sulfonic acid, etc., but is not limited thereto, and preferably, carbachol.
In one aspect of the invention, the content of the aforesaid garcinia cambogia extract is 0.0001 to 30% by weight of the total weight of the composition, and the content of carbachol or a pharmaceutically acceptable salt thereof is 0.0001 to 20% by weight of the total weight of the composition, preferably the content of the aforesaid garcinia cambogia extract is 0.001 to 20% by weight of the total weight of the composition, and the content of carbachol or a pharmaceutically acceptable salt thereof is 0.001 to 10% by weight of the total weight of the composition.
In the present invention, the oral composition may be used in the form of an oral hygiene composition, a pharmaceutical composition, or a food composition, but is not necessarily limited to these forms.
In the present invention, the composition of the present invention can be used for protecting gums or preventing, ameliorating or treating oral diseases.
In the present invention, the oral diseases may include various diseases in the oral cavity which may occur due to the influence of microorganisms in the oral cavity and external physical stimulation, and for example, may include sensitive tooth symptoms in which dentinal tubules are exposed to cause allergic reactions due to abrasion of the tooth surface.
In the present invention, the above oral diseases are general concepts including, for example, but not limited to, sensitive teeth, halitosis, caries, periodontal disease, gingivitis, periodontitis, pulpitis, oral mucositis, stomatitis, oral mucosal ulcer, thrush, lichen planus, other oral inflammatory lesions, and the like.
In the present invention, "prevention" means that all behaviors of a target symptom are inhibited or delayed by administration of the composition of the present invention.
In the present invention, "improvement" means all behaviors that a target symptom is improved or favorably altered by administration of the composition of the present invention as compared with before administration.
In the present invention, "treatment" refers to all actions of ameliorating or eliminating a target disease or medical symptom by administration of the composition of the present invention, and can be used as a concept including improvement.
The term "oral cavity" as used in this specification is intended to mean the entire oral cavity, including lips, gums (gingiva), hard and soft palate, uvula, palatine tonsils, teeth, inside of cheek, tongue and papilla of tongue.
The term "sensitive tooth" used in the present specification is not limited thereto, but means all phenomena of acute, temporary or persistent pain to external stimuli, unlike decayed teeth or other etiologies. The external stimulus is generally referred to as a temperature stimulus, and symptoms generally appear under a cold temperature stimulus, but pain also appears under a hot temperature. In addition to such temperature stimulation, pain may also occur due to stimulation such as drying of teeth, contact with foreign substances, or osmotic pressure through sweet or sour foods. This occurs not only in the entire tooth but also in specific parts such as the upper jaw, the lower jaw, the right side, the left side, and the like, and is accompanied by dentinal hyperesthesia (dentin hyperesthesia), dental caries, and pulpal inflammation.
In still another aspect of the present invention, the Garcinia cambogia extract of the present invention is preferably contained in a composition for preventing, improving or treating sensitive tooth symptoms.
The term "halitosis" as used herein may mean a symptom that an unpleasant odor is emitted from the mouth, but is not limited thereto, and typically, an unpleasant odor may be induced from the mouth due to volatile sulfur compounds (volatile sulfur compounds) generated when microorganisms in the oral cavity decompose proteins.
The term "caries" as used in the present specification refers to caries in which an acid (acid) generated by decomposition of sugar, starch, or the like by bacteria residing in the mouth causes damage to the enamel of a tooth and thus the tooth is produced. The dental caries may occur for various reasons, but for example, dental plaque (plaque) as a bacterial film is formed on the tooth surface.
The term "periodontal disease" as used in the present specification is also called trench-mouth disease (trench mouth) as an oral disease including gingivitis and periodontitis by degree. Periodontal disease causes severe gingivitis, which can result in bleeding, abscess, and pain at the gums, often leading to early loss of teeth. Symptoms of periodontal disease include painful gums, poor breathing, unpleasant bad breath, fever, bleeding gums under weak pressure, crater-sized thrush between teeth and gums, swollen lymph nodes around the head, neck or chin, gray membranes on gums, red gums, swollen gums, and pain when eaten or swallowed.
The term "gingivitis" as used in this specification is defined as inflammation of the gums (gum) and as an abnormality (disorder) characterised by periodontal disease, which is characterized by the destruction of the gums, tissues, pockets and ligaments constituting the structure that holds the teeth in place. Gingivitis is one of the first stages of severe periodontal disease. Symptoms of gingivitis include swollen gums, burning pain in the mouth, a bright red or purple appearance on the gums, smooth gums, no pain on the gums other than when touched with the hands, and bleeding gums.
The term "periodontitis" (or alveolar Pyorrhea) as used in this specification is an inflammation of periodontal tissues including tissues supporting teeth in the oral cavity. The parts included in the periodontal tissue are gingiva (gum tissue), alveolar bone (i.e., pockets to which teeth are attached), cementum or outer layer of the tooth root, and periodontal ligament or PDL consisting of connective tissue fibers connecting gingiva and cementum to alveolar bone. Symptoms are described as progressive loss of bone around the teeth that loosens the teeth or loss of teeth if left alone. Periodontitis is considered to be a progressive form of gum disease because it has been accompanied by bone loss in the related art.
The term "pulpitis" (pulpitis) used in the present specification is an inflammation occurring in the dental pulp inside a tooth in which many nerves and blood vessels are distributed, and means that the dental pulp tissue is invaded and becomes involved in necrosis due to temperature stimulation, chemical stimulation, bacterial stimulation, and the like. When a blood vessel expands and blood flow increases with the release of inflammatory factors in response to a harmful stimulus, and thus a tissue edema occurs, the final result of the inflammatory reaction is different from other tissues because the pulp exists in a limited space surrounded by hard dentin, unlike general tissues.
The term "oral mucositis" as used in the present description is understood to mean the clinical symptoms in the oral cavity characterized by the presence of painful symptomatology complexes and by reduced epithelial thickness, intense erythema and ulceration associated with possible infections and haemorrhages, and according to the case includes stomatitis and ulceration of the oral mucosa.
The term "Stomatitis" (Stomatitis) as used in the present specification refers essentially to oral inflammation, but more specifically, Stomatitis is inflammation of the mucous lining of the oral cavity which may include the gums, tongue, cheeks, lips and floor or upper bore. Stomatitis is classified according to how humans acquire the above-mentioned disease. Contact stomatitis is an inflammation of the oral mucosa caused by contact with an allergen or irritant. Aphthous stomatitis (also known as ulcerative stomatitis or aphthous ulcer) has an unknown etiology. Ulcerative stomatitis, like contact stomatitis, affects the oral mucosa. Aphthous ulcers are a form of oral ulcers that manifest as an open pain (pain) in the inside of the mouth or upper throat (including the uvula) caused by mucosal disruption.
The term "ulcer of the oral mucosa" used in the present specification is also referred to as stomatitis (stomatis), and although not limited thereto, may include diseases in which inflammation occurs at the oral mucosa (tongue, gum, lips, inner side of cheek, etc.) due to infection by bacteria, viruses, fungi, etc. in the oral cavity.
The term "thrush" as used in this specification is a disease in which the fungus Candida albicans (Candida albicans) rapidly grows in an uncontrolled manner in the oral cavity. Bacteria known as flora (flora) control the growth of candida albicans in a healthy body. Thrush presents a creamy white paste covering the tongue and can spread rapidly into the palate, gums, back of the throat, tonsils and inside the cheeks.
The term "Lichen planus" (Lichen planus) as used in this specification is generally defined as an oral disease affecting the oral cavity with inflammation. Lichen planus is generally considered to be a rash that irritates the tissues of the oral cavity. Lichen planus also occurs in the skin as a skin disease, often in order to distinguish it from oral lichen planus, and is particularly called cutaneous lichen planus.
The term "other oral inflammatory conditions" as used in this specification may be used to treat other forms of oral inflammation (including but not limited to oral ulcers caused by mucositis, viral, bacterial, fungal or protozoal infections or by abnormalities in the immune system (immunodeficiency, autoimmunity or allergy)). Also included are oral submucosa fibrosis, chronic debilitating diseases of the oral cavity characterized by inflammation, and progressive fibrosis of submucosal tissues. It also includes glossitis, inflammation or infection of the tongue.
The present invention provides an oral hygiene composition for the protection of gums or the prevention or improvement of oral diseases, comprising an extract of Garcinia cambogia as an active ingredient. Further, the present invention provides an oral hygiene composition for the prevention or improvement of gum protection or oral diseases, comprising an extract of Garcinia cambogia and carbachol or a pharmaceutically acceptable salt thereof as active ingredients.
The oral hygiene compositions of the present invention include all kinds and dosage forms that can be used for oral hygiene. Non-limiting examples of the above oral hygiene composition may be exemplified by toothpastes, oral cleansers, oral sprays, oral ointments, oral patches, chewing gums and the like.
When the oral hygiene composition of the present invention is a toothpaste, it may further contain an abrasive, a binder, a humectant, a foaming agent, a sweetener, a whitening agent, or a flavoring agent, in addition to the garcinia cambogia extract as an active ingredient. The above-mentioned abrasive may be used singly or in combination of aluminum hydroxide, anhydrous silicic acid, aluminum silicate, calcium hydrogen phosphate, dihydroxide and anhydride, tricalcium phosphate, calcium carbonate, calcium pyrophosphate, insoluble sodium metaphosphate, trimagnesium phosphate, magnesium carbonate, calcium sulfate, polymethyl methacrylate, etc.
When the oral hygiene composition is a paste composition, the binder may be used singly or in combination of carrageenan, various thickening cellulose derivatives, gums such as xanthan gum and tragacanth gum (tragacanth gum), organic binders such as polyvinyl alcohol, sodium polyacrylate, polyacrylic acid/maleic acid copolymer and synthetic polymer derivatives such as carboxyvinyl polymer, and inorganic binders such as silica and laponite.
In addition, the above oral hygiene composition may further comprise sorbitol, glycerin, ethylene glycol, propylene glycol, polyether glycol, polypropylene glycol, or the like as a humectant during its preparation.
In addition, the oral hygiene composition may further comprise a flavor, a sweetener, or the like. The sweetener can be sucrose, lactose, maltose, sorbitol, xylitol, sodium cyclamate, glycerol, saccharin sodium, stevioside, aspartame, etc., the spice can be mint, menthol, anethole, eugenol, limonene, citronellol, alpha-terpineol, salicylylmethyl (salicylmethyl), eucalyptol, linalool, ethyl linalool, vanillin, thymol, spearmint oil, sage oil, rosemary oil, cinnamon oil, etc., and the sweetener or spice can be used alone or in combination.
In addition, the oral hygiene composition of the present invention may comprise a surfactant or an additional efficacy ingredient, alone or in combination, as a foaming ingredient. The above-mentioned surfactant used as the foaming component may be any one selected from the group consisting of an anionic surfactant, a nonionic surfactant and a cationic surfactant.
When the oral hygiene composition of the present invention is a toothpaste, it may be prepared by a conventional toothpaste preparation method in addition to containing the garcinia cambogia extract as an effective ingredient, and when the oral hygiene composition of the present invention is a mouthwash solution, it may be prepared by mixing the garcinia cambogia extract in a conventional solution and formulating into a mouthwash solution, and oral diseases may be prevented or treated by washing the oral cavity 2 to 10 times per day.
In addition, when the oral hygiene composition of the present invention is a toothpaste cream, a liquid containing water and a humectant, a gelling agent or a water-insoluble gloss agent, a sweetener, a flavor, and the like may be further included.
In addition, when the oral hygiene composition of the present invention is a mouth rinse (cleanser), it may further comprise a toothpaste carrier, more specifically a non-toxic alcohol.
For the oral hygiene composition of the present invention, the following contents of pharmaceutical composition, pharmaceutical external composition and food composition may be applicable.
In addition, the present invention provides a pharmaceutical composition for the protection of gums or the prevention, improvement, or treatment of oral diseases, comprising an extract of garcinia cambogia as an active ingredient. Further, the present invention provides a pharmaceutical composition for the prevention, amelioration or treatment of gum protection or oral diseases, comprising an extract of Garcinia cambogia and carbachol or a pharmaceutically acceptable salt thereof as active ingredients.
In one aspect of the present invention, in the pharmaceutical composition of the present invention, the content of the above-mentioned garcinia cambogia extract is 0.0001 to 30 wt% of the total weight of the composition, preferably 0.001 to 20 wt% of the total weight of the composition.
In another aspect of the present invention, in the pharmaceutical composition of the present invention, the above-mentioned garcinia cambogia extract is contained in an amount of 0.0001 to 30 wt% and carbachol or a pharmaceutically acceptable salt thereof is contained in an amount of 0.0001 to 20 wt% based on the total weight of the composition, preferably, the above-mentioned garcinia cambogia extract is contained in an amount of 0.001 to 20 wt% and carbachol or a pharmaceutically acceptable salt thereof is contained in an amount of 0.001 to 10 wt% based on the total weight of the composition.
In one aspect of the present invention, the pharmaceutical composition of the present invention may exert a preventing, ameliorating or treating effect on any one or more diseases selected from the group consisting of sensitive teeth, halitosis, caries, periodontal disease, gingivitis, periodontitis, pulpitis, oral mucositis, stomatitis, oral mucosal ulcer, thrush, lichen planus and other oral inflammatory lesions.
The pharmaceutical compositions of the present invention may be prepared according to methods commonly prepared in the industry for preparing the same.
In the present invention, the pharmaceutical composition of the present invention may comprise the above-mentioned Garcinia cambogia extract alone as an active ingredient, and may further comprise additional ingredients, i.e., pharmaceutically acceptable carriers, excipients, diluents or sub-ingredients, depending on the dosage form, method of use and purpose of use.
In the present invention, the pharmaceutical composition of the present invention may also be used in a single formulation, and may be used by further comprising a drug known to have a preventive, ameliorating or therapeutic effect on gum protection or oral diseases and preparing a complex formulation.
The pharmaceutical composition may further contain, in addition to the above active ingredients, nutrients, vitamins, electrolytes, flavors, colorants, enhancers, pectic acids and salts thereof, alginic acid and salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonating agents used for carbonated beverages, and the like. In addition, the above-mentioned carrier, excipient or diluent may be one or more selected from the group consisting of lactose, glucose (dextrose), sucrose, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, gum arabic, alginate, gelatin, calcium phosphate, calcium silicate, cellulose, methyl cellulose, microcrystalline cellulose, polyvinylpyrrolidone, water, methyl hydroxybenzoate, propyl hydroxybenzoate, talc, magnesium stearate, and mineral oil, dextrin, calcium carbonate, propylene glycol, liquid paraffin, physiological saline, but is not limited thereto, and a conventional carrier, excipient or diluent may be used.
The above pharmaceutically allowable carrier, excipient or diluent is not limited as long as it does not impair the effects of the present invention, and for example, may include a filler, a bulking agent, a binder, a wetting agent, a disintegrating agent, a surfactant, a lubricant, a sweetener, a fragrance, an anti-aggregating agent, a perfume, an emulsifier, a preservative, etc., and may be used orally or non-orally.
In the present invention, solid preparations for oral administration include tablets, pills, powders, granules, capsules and the like, and these solid preparations are prepared by mixing at least one or more excipients, such as starch, calcium carbonate (calcium carbonate), sucrose (sucrose) or lactose (lactose), gelatin and the like, with the above garcinia cambogia extract. In addition, lubricants such as magnesium stearate, talc are used in addition to simple excipients. Liquid preparations for oral administration include suspensions, solutions for contents, emulsions, syrups and the like, and may include various excipients such as wetting agents, sweeteners, aromatics, preservatives and the like, in addition to water, liquid paraffin, which is a simple diluent commonly used.
In the present invention, the form for non-oral administration may be exemplified by toothpaste, mouth cleanser, topical agent (cream, ointment, dressing solution, spray, other coating agent, etc.), and the like. As an example of the dosage form of the above topical administration agent, there can be mentioned one in which a pharmaceutical composition containing an extract of garcinia cambogia as an active ingredient is impregnated in a carrier such as gauze made of natural fibers or synthetic fibers.
The cream or ointment can be applied directly to affected part of gingivitis, periodontitis or to part of tooth decay or its periphery. As for the above spray, in addition to containing the garcinia cambogia extract as an effective ingredient, it can be prepared by a conventional spray preparation method, and oral diseases can be prevented or treated by filling the package in a compressed container or other spray container and spraying it on the oral disease site at any time. As for the above dressing solution, in addition to containing the garcinia cambogia extract as an effective ingredient, it can be prepared by a conventional preparation method of the dressing solution, and it can prevent or treat an oral infection disease by applying to an oral disease site or a dressing for other bacterial infection sites.
In addition, depending on the method of use, the dosage form of the pharmaceutical composition of the present invention may be in a preferred form, and in particular may be formulated using methods known in the art so as to provide rapid, sustained or delayed release of the active ingredient after administration to the mammal. Examples of the specific dosage form include plaster, granule, lotion, liniment, lemon water agent, powder, syrup, liquid, aerosol, extract (extrcts), medicament, ointment, fluid extract, emulsion, suspension, decoction, extract, tablet, capsule, cream, pill, soft or hard gelatin capsule and the like, but are not limited to these dosage forms.
In the present invention, the above-mentioned pharmaceutical composition can be administered in a pharmaceutically effective amount. The above "pharmaceutically effective amount" means an amount sufficient to prevent the oral disease or treatment-related disease of the present invention with a reasonable benefit or risk ratio applicable to medical treatment. The effective dose level may be determined according to factors including the kind and severity of an individual, age, sex, activity of a drug, sensitivity to a drug, administration time, administration route and excretion rate, treatment period, concurrent use of a drug, and other factors well known in the medical field. For example, the administration may be performed once or several times per day. The above amounts of administration do not limit the scope of the invention in any way.
In addition, the pharmaceutical composition of the present invention may contain known compounds or plant extracts having an oral disease inhibitory activity in addition to the garcinia cambogia extract, and may be contained in a specific amount according to the preparation method and the purpose of use.
The pharmaceutical composition of the present invention can be applied to the oral hygiene composition described above, the pharmaceutical external composition described below, and the food composition described below.
In addition, the present invention provides a pharmaceutical composition for external use for the protection of gums or the prevention or improvement of oral diseases, comprising an extract of Garcinia cambogia as an active ingredient. The present invention also provides a pharmaceutical composition for external use for preventing or improving gum protection or oral diseases, which comprises an extract of Garcinia cambogia and carbachol or a pharmaceutically acceptable salt thereof as active ingredients.
The pharmaceutical composition of the present invention may contain, in addition to the above-mentioned active ingredients, carriers, excipients, or diluents which are generally used in pharmaceutical compositions for external use, as necessary, within a range not to impair the object of the present invention. The above-mentioned carrier, excipient or diluent is not limited as long as it does not impair the effects of the present invention, and for example, may include a filler, a bulking agent, a binder, a wetting agent, a disintegrant, a surfactant, a preservative, a flavor, a dispersing agent, a viscosity modifier, a pH modifier, a lubricant, a sweetener, a preservative, and the like.
The contents of the oral hygiene composition, the pharmaceutical composition and the food composition described below are applicable to the pharmaceutical composition of the present invention.
In yet another aspect of the invention, the invention provides a product, i.e. an oral hygiene product, a pharmaceutical product, a parenteral product or a food product, comprising the composition of the invention.
In addition, the present invention provides a food composition for protecting gums or preventing or improving oral diseases, comprising an extract of Garcinia cambogia as an active ingredient. Further, the present invention provides a food composition for protecting or improving gums or preventing or improving oral diseases, comprising an extract of Garcinia cambogia and carbachol or a pharmaceutically acceptable salt thereof as active ingredients.
In one aspect of the present invention, in the food composition of the present invention, the content of the above garcinia cambogia extract is 0.0001 to 30% by weight, preferably 0.001 to 20% by weight, based on the total weight of the composition.
In another aspect of the present invention, in the food composition of the present invention, the above-mentioned garcinia cambogia extract is contained in an amount of 0.0001 to 30% by weight and carbachol or a pharmaceutically acceptable salt thereof is contained in an amount of 0.0001 to 20% by weight, preferably, the above-mentioned garcinia cambogia extract is contained in an amount of 0.001 to 20% by weight and carbachol or a pharmaceutically acceptable salt thereof is contained in an amount of 0.001 to 10% by weight, based on the total weight of the composition.
In one aspect of the present invention, the food composition of the present invention may exert a preventing or improving effect on any one or more diseases selected from the group consisting of sensitive teeth, halitosis, caries, periodontal disease, gingivitis, periodontitis, pulpitis, oral mucositis, stomatitis, oral mucosal ulcer, thrush, lichen planus, and other oral inflammatory lesions.
In one aspect of the present invention, the food composition of the present invention may exert a preventing or improving effect on any one or more diseases selected from the group consisting of sensitive teeth, halitosis, caries, periodontal disease, gingivitis, periodontitis, pulpitis, oral mucositis, stomatitis, oral mucosal ulcer, thrush, lichen planus, and other oral inflammatory lesions. Preferably, the prevention or improvement of the symptoms of sensitive teeth can be effected.
In the present invention, the food composition of the present invention may further comprise suitable carriers, excipients and diluents commonly used in the preparation thereof.
The term "food" as used herein refers to a natural or processed product containing one or more nutrients, preferably, refers to those which become directly eatable through a certain degree of processing, and generally includes all foods, food additives, functional foods, drinks, drink additives, functional drinks and the like.
The term "functional food" as used herein refers to a group of foods that can impart added value to foods by physical, biochemical, bioengineering methods or the like so as to express the functional action of the foods to a specific purpose, or foods that are designed and processed so as to sufficiently express the body regulation functions related to the regulation of the rhythm of defense of living organisms, the prevention and recovery of diseases, and the like, which are possessed by the food composition, to living organisms, and preferably, the functional food of the present invention refers to a food that can sufficiently express the body regulation functions related to the prevention or improvement of gum protection or oral diseases to living organisms. The above functional food may include food auxiliary additives allowable in terms of food science, and may further include suitable carriers, excipients and diluents generally used in preparing functional foods.
The term "beverage" used in the present specification means a general term of those drunk for quenching thirst or enjoying taste, and is intended to include functional beverages. The above beverage is not particularly limited except that the above active ingredient is contained as an essential ingredient in the indicated ratio, and various flavors or natural carbohydrates and the like may be contained as additional ingredients as in the ordinary beverage.
In addition to the above, the composition of the present invention may contain various nutrients, vitamins, minerals (electrolytes), flavors such as synthetic flavors and natural flavors, colorants and enhancers (cheese, chocolate, etc.), pectic acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohol, carbonating agents used for carbonated beverages, and the like. These ingredients may be used independently or in combination.
The term "functional beverage" as used herein refers to a group of beverages which are added with value to beverages by physical, biochemical, or biological engineering methods to express the functional effects of the beverages to a specific purpose, or a beverage which is designed and processed so as to sufficiently express the body-regulating functions related to the regulation of the rhythm of defense of living organisms, the prevention and recovery of diseases, and the like, which are possessed by the beverage composition, to living organisms.
The above-mentioned functional beverage is not particularly limited except that it contains the Garcinia cambogia extract of the present invention as an essential ingredient in the indicated ratio, and may contain various flavors or natural carbohydrates, etc. as additional ingredients, as in ordinary beverages.
For the food composition of the present invention, the contents of the above oral hygiene composition, pharmaceutical composition and pharmaceutical external composition may be applicable.
All the ingredients recited in the present invention preferably do not exceed the maximum use values stipulated in the relevant regulations, specifications (e.g., food code (korea), food additive code (korea), health functional food code (korea), sanitary code (china)) of korea, china, the united states, europe, japan, etc. That is, the composition of the present invention preferably contains the ingredients of the present invention in the content limit permitted in the relevant laws and regulations of each country.
ADVANTAGEOUS EFFECTS OF INVENTION
The composition comprising the garcinia cambogia extract of the present invention as an active ingredient has a gingival protection or oral disease prevention, improvement, or treatment effect. In addition, the composition of the present invention uses natural materials of plant origin, and thus has little side effect, is safe to the human body, and exhibits excellent effects. In particular, the composition exhibits an excellent effect on the prevention, amelioration or treatment of sensitive tooth symptoms.
In addition, a composition comprising the Garcinia cambogia extract of the present invention and carbachol or a pharmaceutically acceptable salt thereof as active ingredients provides a gingival protective or oral disease preventing, improving or treating effect. By combining and using these active ingredients, the above effects are synergistically enhanced, and thus the effects are more excellent.
Drawings
FIG. 1 shows the results of experiments to confirm the inhibitory effect of the composition of the present invention on IL-6.
FIG. 2 shows the results of experiments to confirm the inhibitory effect of the composition of the present invention on PGE 2.
FIG. 3 shows the results of experiments in which the inhibitory effect of the composition of the present invention on MMP1 and MMP3 was confirmed.
Detailed Description
Hereinafter, in order to assist understanding of the present invention, a detailed description will be given by way of examples and the like. However, the embodiments of the present invention may be modified into various different forms, and the scope of the present invention should not be construed as being limited to the following embodiments. Embodiments of the present invention are provided to more fully describe the present invention to those of ordinary skill in the art.
Preparation example preparation of Garcinia cambogia extract
The garcinia cambogia extract of the present invention was prepared by the following method. Garcinia cambogia extract was purchased from JuYeong NS company for use.
Experimental example 1 inflammatory response experiment
(Experimental method)
THP-1 (human monocytic cells) was plated in RPMI1640 medium supplemented with 10% FBS and PMA (ug/ml) at 2X 10/ml in each well of 24-well plates5Cells/well (cells/well) were plated and incubated with 5% CO at 37 deg.C2Cultured for 24 hours, and differentiated into macrophages (macrophages).
Garcinia cambogia extract and/or carbachol were pretreated for 1 hour, and then e.
The ELISA was performed by dilution (dilution) of the Supernatant (supranatant).
(results)
IL-6 shown in FIG. 1 is a cytokine involved in the initial inflammatory response, and plays various roles in immune response regulation such as leukocyte transport and activation, and differentiation and activation of T cells and B cells. As shown in fig. 1, it was confirmed that garcinia cambogia extract can reduce inflammation such as gingivitis and periodontitis by inhibiting cytokines involved in inflammatory and pain response. In particular, when the garcinia cambogia extract and the carbachol are used together, the effect of reducing inflammation such as gingivitis and periodontitis by suppressing cytokines involved in inflammation and pain reaction is more excellent.
PGE2 shown in figure 2 is prostaglandin E2(PGE2) which is a marker of pain and inflammation. As shown in fig. 2, it was confirmed that the garcinia cambogia extract can reduce inflammation such as gingivitis and periodontitis by inhibiting cytokines involved in inflammatory and pain response. In particular, when the garcinia cambogia extract and the carbachol are used together, the effect of reducing inflammation such as gingivitis or periodontitis by suppressing cytokines involved in inflammation and pain reaction is more excellent.
That is, it was confirmed that the Garcinia cambogia extract and the mixture of Garcinia cambogia extract and carbachol have an effect of reducing inflammation in gingivitis and periodontitis by suppressing inflammatory reaction.
Experimental example 2 inhibition effect of MMP1, 3
(Experimental method)
HGF-1 (human gingival fibroblast) was cultured in 10% FBS-supplemented DMEM medium at 2 x 10 in each well of 6-well plate5Cells/well plated and incubated with 5% CO at 37 deg.C2The culture was carried out for 24 hours.
Garcinia cambogia extract and/or carbachol were pretreated for 1 hour, and then e.
Cell lysis (Cell lysis) was performed and RNA prep, cDNA synthesis, real-time PCR was performed to observe the expression of MMPs 1, 3.
(results)
MMPs shown in fig. 3 (more specifically, MMP1 and MMP3) are enzymes capable of decomposing gingival tissues including collagen with matrix metalloproteinases (matrix metalloproteinases). As shown in fig. 3, it was confirmed that the Garcinia cambogia extract can reduce the decomposition of gum tissue by inhibiting the expression of MMP by LPS. In particular, when the garcinia cambogia extract and carbachol are used together, the effect of reducing the decomposition of the gum tissue by suppressing the expression of MMP by LPS is more excellent.
[ Table 1]
Experimental example 3 inhibition of gingival inflammation formation
(Experimental method)
Toothpaste for control group and experimental group containing Garcinia cambogia extract and/or carbachol was prepared, and clinical trials were conducted with patients with gingival inflammation as subjects.
Control group: common toothpaste using sodium carboxymethylcellulose, sodium lauryl sulfate, glycerin, colloidal silicon dioxide, silicas, sodium cocoyl isethionate, DDENIA (dodicin), and sweeteners, aromatics, colorants, etc
Experimental group 1: control group + Garcinia cambogia extract 0.01 wt%
Experimental group 2: control + carbachol 0.01% by weight
Experimental group 3: control group + Garcinia cambogia extract 0.005 wt% + carbachol 0.005 wt%
Subject: the patients with gingival inflammation with uniform dentition and no defective teeth were subjected to precise oral examination every 30 patients with age from 30 to 50 years at 10 years intervals according to sex, and 40 groups of subjects were selected and then divided into 10 patients.
The use times are as follows: after 2 hours after meals, the product is taken 3 times a day before sleep.
Measurement of gingivitis index: the initial gingivitis index was scored by performing a tooth surface scrub such that oral examinations were performed to check the gingivitis index after 1 week, 1 month, 3 months using each toothpaste composition. A periodontal probe (periodontal probe) was inserted into the gingival fissure, the vicinity of each tooth was burned and probed without applying force, and the bleeding state was measured after 30 seconds.
Table 2 below shows the gingivitis index criteria.
[ Table 2]
| Score of | Content providing method and |
| 0 point (min) | No bleeding state |
| 1 minute (1) | State of normal bleeding |
| 2 is divided into | Linear bleeding state |
| 3 points of | Triangular bleeding state of interdental area |
| 4 is divided into | Bleeding state of whole gum |
(results of experiments)
The degree of inflammation of the control group was severe, 1.52, from the lapse of 1 week, and the inflammation had worsened even after the lapse of 3 months.
The test groups 1, 2 and 3 all showed a low degree of inflammation, and particularly, the combined test group of Garcinia cambogia extract and carbachol (test group 3) showed the lowest degree of inflammation even though the contents of the respective components were small, as compared with the test groups 1 and 2.
The experimental results are shown in Table 3 below (unit: min).
[ Table 3]
| Time | Control group | Experimental group 1 | Experimental group 2 | Experimental group 3 |
| 0 week | 1.04±0.04 | 1.05±0.02 | 1.04±0.03 | 1.06±0.02 |
| 1 week | 1.52±0.01 | 1.11±0.03 | 1.12±0.02 | 1.07±0.05 |
| 1 month | 2.50±0.03 | 1.17±0.07 | 1.19±0.05 | 1.10±0.02 |
| 3 months old | 2.83±0.09 | 1.18±0.08 | 1.21±0.02 | 1.13±0.01 |
Experimental example 4 sensitive teeth inhibitory Effect experiment
(Experimental method)
Control group and experimental group toothpastes containing Garcinia cambogia extract and/or carbachol were prepared and subjected to clinical trials.
Control group: common toothpaste using sodium carboxymethylcellulose, sodium lauryl sulfate, glycerin, colloidal silicon dioxide, silicas, sodium cocoyl isethionate, DDER and sweetener, flavoring agent, coloring agent, etc
Experimental group 1: control group + Garcinia cambogia extract 0.01 wt%
Experimental group 2: control + carbachol 0.01% by weight
Experimental group 3: control group + Garcinia cambogia extract 0.005 wt% + carbachol 0.005 wt%
Subject: the number of volunteers who agreed to participate in the experiment with human subjects having dentinal hypersensitivity teeth was 40, and the total number of subjects had 80 teeth. The above 40 volunteers were 20 women and 20 men aged 20 to 50 years.
The use times are as follows: after 2 hours after meals, the product is taken 3 times a day before sleep for 2 weeks.
Measurement: after application of the temperature stimulus, the patient's response was measured. Before the test was performed, the sensitive site of the hyperesthetic tooth of each volunteer was examined in advance, and cold water of about 5 ℃ was dropped on the sore site of the tooth with a dropper to perform scoring. After 2 weeks, a drop of cold water at about 5 ℃ was again applied with a dropper for scoring.
For statistical treatment, the stimulation scores before and after 2 weeks of experiment implementation were examined by paired student-t test (paired student-t test).
Table 4 below shows the reaction scoring criteria.
[ Table 4]
| Score of | Content providing method and |
| 0 point (min) | Has no discomfort. |
| 1 minute (1) | Slight discomfort or soreness. |
| 2 is divided into | Very uncomfortable or sore. |
| 3 points of | Pain is caused. |
(results of experiments)
The experimental groups 1, 2 and 3 all had sensitive tooth inhibitory effects, and in particular, the combined experimental group of garcinia cambogia extract and carbachol (experimental group 3) had superior sensitive tooth inhibitory effects even though the contents of the respective components were small, as compared with the experimental groups 1 and 2.
The results of the experiment on the degree of inhibition of sensitive teeth are shown in the following table 5 (unit: point).
[ Table 5]
| Time | Control group | Experimental group 1 | Experimental group 2 | Experimental group 3 |
| 0 week | 2.13±0.09 | 2.14±0.07 | 2.13±0.11 | 2.14±0.10 |
| 2 weeks | 2.14±0.10 | 1.73±0.12 | 1.76±0.09 | 1.62±0.11 |
| P-value | p>0.05 | *p<0.05 | *p<0.05 | *p<0.05 |
Experimental example 5 halitosis-suppressing Effect experiment
(Experimental method)
Toothpaste of control group and experimental group containing Garcinia cambogia extract and/or carbachol were prepared and subjected to clinical trial.
Control group: common toothpaste using sodium carboxymethylcellulose, sodium lauryl sulfate, glycerin, colloidal silicon dioxide, silicas, sodium cocoyl isethionate, DDER and sweetener, flavoring agent, coloring agent, etc
Experimental group 1: control group + Garcinia cambogia extract 0.01 wt%
Experimental group 2: control + carbachol 0.01% by weight
Experimental group 3: control group + Garcinia cambogia extract 0.005 wt% + carbachol 0.005 wt%
Subject: 50 men and women without caries were screened and subject beverages were subjected to cross-over test (cross-over test).
The source of the halitosis is: commercially available garlic powder was dispersed in water, left to stand for 24 hours, and then diluted. Hammett (Halimeter) measures over 700 ppb.
Measurement: gargle with 15ml of garlic powder diluent for 30 seconds, measure the degree of halitosis with Haiming after 1 minute, and brush teeth with toothpaste of control group and experimental group for 30 seconds-1 minute. After 1 minute, 5 minutes, and 30 minutes after brushing, the degree of halitosis was measured using Haiminet.
(results of experiments)
The test group showed a better halitosis-suppressing effect than the control group for 30 minutes, and particularly, the combination test group (test group 3) of Garcinia cambogia extract and carbachol showed a better halitosis-suppressing effect than the test groups 1 and 2 even though the contents of the respective components were small. The inhibition of halitosis is shown in table 6 below.
[ Table 6]
| Time | Control group | Experimental group 1 | Experimental group 2 | Experimental group 3 |
| 1 minute | 57.6％ | 95.2％ | 82.7％ | 98.3％ |
| 5 minutes | 46.9％ | 92.6％ | 78.1％ | 95.2％ |
| 30 minutes | 39.2％ | 89.4％ | 70.3％ | 93.7％ |
Claims (9)
1. An oral hygiene composition for the prevention or improvement of gum protection or oral diseases, comprising an extract of Garcinia Cambogia (Garcinia Cambogia) as an effective ingredient.
2. A pharmaceutical composition for the prevention, amelioration or treatment of gum protection or oral diseases, which comprises Garcinia cambogia extract as an effective ingredient.
3. A pharmaceutical composition for external use for preventing or improving gum protection or oral diseases, which comprises Garcinia cambogia extract as an active ingredient.
4. The composition according to any one of claims 1 to 3, wherein the oral disease is any one or more diseases selected from the group consisting of sensitive teeth, halitosis, caries, periodontal disease, gingivitis, periodontitis, pulpitis, oral mucositis, stomatitis, oral mucosal ulcers, thrush, lichen planus and other oral inflammatory lesions.
5. The composition of claim 4, wherein the oral disease is sensitive teeth.
6. An oral hygiene composition for the prevention or improvement of gum protection or oral diseases, comprising an extract of Garcinia cambogia; and carbachol (Carbazochrome) or a pharmaceutically acceptable salt thereof as an active ingredient.
7. A pharmaceutical composition for the prevention, amelioration or treatment of gum protection or oral diseases, which comprises Garcinia cambogia extract and carbachol or a pharmaceutically acceptable salt thereof as active ingredients.
8. A pharmaceutical composition for external use for preventing or improving gum protection or oral diseases, which comprises Garcinia cambogia extract and carbachol or a pharmaceutically acceptable salt thereof as active ingredients.
9. The composition according to any one of claims 6 to 8, wherein the oral disease is any one or more diseases selected from the group consisting of sensitive teeth, halitosis, caries, periodontal disease, gingivitis, periodontitis, pulpitis, oral mucositis, stomatitis, oral mucosal ulcers, thrush, lichen planus and other oral inflammatory lesions.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020200170119A KR20220080874A (en) | 2020-12-08 | 2020-12-08 | Oral composition |
| KR10-2020-0170119 | 2020-12-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN114601760A true CN114601760A (en) | 2022-06-10 |
Family
ID=81857580
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110917912.5A Pending CN114601760A (en) | 2020-12-08 | 2021-08-11 | Oral composition |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR20220080874A (en) |
| CN (1) | CN114601760A (en) |
-
2020
- 2020-12-08 KR KR1020200170119A patent/KR20220080874A/en active Search and Examination
-
2021
- 2021-08-11 CN CN202110917912.5A patent/CN114601760A/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20220080874A (en) | 2022-06-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102408893B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
| KR20170141053A (en) | Composition for prevention or treatment of dental disease comprising an extract of Gardenia jasminoides | |
| CN112236148A (en) | Composition for preventing or treating oral diseases | |
| KR102562835B1 (en) | Composition for prevention or treatment of oral disease comprising ROSAE LAEVIGATAE Extract | |
| US20090232749A1 (en) | Compositions for the acute and/or long term treatment of periodontal diseases | |
| KR20200050801A (en) | Oral composition containing eugenol and bamboo salt | |
| KR20200041659A (en) | Composition for prevention or treatment of oral disease | |
| KR101881636B1 (en) | Composition for prevention or treatment of oral disease comprising Pueraria Extract | |
| CN114601760A (en) | Oral composition | |
| KR102415612B1 (en) | Composition for prevention or treatment of oral disease comprising Melonis Pedicellus Extract | |
| KR102548925B1 (en) | Composition for prevention or treatment of oral disease comprising Scopoletin | |
| KR20180047705A (en) | Composition for prevention or treatment of oral disease comprising Forsythiae Fructus extract | |
| KR20180047704A (en) | Composition for prevention or treatment of oral disease comprising Scutellaria baicalensis extract | |
| KR20180047703A (en) | Composition for prevention or treatment of oral disease comprising Nelumbo Nucifera extract | |
| KR100665891B1 (en) | Oral hygiene compositions containing hydroxytyrosol | |
| KR20170103482A (en) | Composition for prevention or treatment of oral disease comprising Glechoma hederacea extract | |
| KR102541843B1 (en) | Composition for prevention or treatment of oral disease comprising Arctiin | |
| KR102562829B1 (en) | Composition for prevention or treatment of oral disease comprising Alpinia officinarum Extract | |
| KR20180046247A (en) | Composition for prevention or treatment of oral disease comprising Verbascoside | |
| KR102564564B1 (en) | Composition for prevention or treatment of oral disease comprising 2-methoxycinnamaldehyde | |
| KR102417082B1 (en) | Composition for prevention or treatment of oral disease comprising Celosia argentea Extract | |
| KR101818211B1 (en) | Composition for prevention or treatment of oral disease comprising Arctill fructus Extract | |
| KR102580941B1 (en) | Composition for prevention or treatment of oral disease comprising Qucercetin 3-glucoside | |
| KR102562831B1 (en) | Composition for prevention or treatment of oral disease comprising Gleditsiae fructus Extract | |
| KR102562830B1 (en) | Composition for prevention or treatment of oral disease comprising Kochiae Fructus Extract |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |